Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05521191 · ClinicalTrials.gov registry record · Phase 1
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
A Phase 1 study, sponsored by Regulus Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT05521191 is a Phase 1 study that has completed, run by Regulus Therapeutics. The registered enrollment target is 68 participants.
The verdict
NCT05521191, a Phase 1 study, has completed, sponsored by Regulus Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
Primary Objectives * To assess the safety and tolerability of RGLS8429 * To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives * To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) * To characterize the pharmacokinetic (PK) properties of RGLS8429 * To assess the impact of RGLS8429 on renal function
Interventions
- DRUG Placebo
- DRUG RGLS8429
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2025-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05521191
The ClinicalTrials.gov registry entry for NCT05521191 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regulus Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05521191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05521191 about?
NCT05521191 is a clinical study titled "A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease". Primary Objectives * To assess the safety and tolerability of RGLS8429 * To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives * To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) * To characterize the pharmacokinetic (PK) properties of RGLS8429 * ...
What is the current status of trial NCT05521191?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2022-10-06. Estimated completion is 2025-03-27.
What interventions are being tested in trial NCT05521191?
The interventions under investigation include: Placebo (DRUG), RGLS8429 (DRUG).
Who is sponsoring clinical trial NCT05521191?
This trial is sponsored by Regulus Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.